VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AMRN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AMRNAmarin Corporation plc
$11.27$235M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksAMRNFinancials

Amarin Corporation plc (AMRN) Income Statement

30Y historyFree accessUpdated daily

Revenue has fallen sharply from $72.7M in 2025Q2 to $39.5M in 2026Q3 while gross margin recovered to 40.9%, but operating margin remained negative at -6.0% in 2026Q3, suggesting cost normalization has not yet translated into operating profitability.

Income StatementBalance SheetCash FlowRatios

AMRN Income Statement

Annual statement

AMRN Income Statement

Amarin Corporation plc (AMRN) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Aug'98Aug'97Aug'96
Sales/Revenue176.04M213.65M228.61M306.91M369.19M583.19M614.06M429.75M229.21M181.1M130.08M81.76M54.2M26.35M000007.37M500K500K1.02M7.37M65.51M4.99M15.74M11.22M10M24.3M21.5M
Revenue Growth %-22.36%-6.55%-25.51%-16.87%-36.69%-5.03%42.89%87.49%26.56%39.22%59.11%50.84%105.69%------100%1373%0%-50.84%-86.19%-88.76%1211.96%-68.27%40.29%12.18%-58.85%13.02%-26.12%
Cost of Goods Sold104.67M92.78M147.23M141.37M126.71M121.33M131.44M96.02M54.54M44.95M34.36M27.88M20.48M11.91M451.33K100.43K99.97K581.82K0000107K11.91M30.13M21.46M4.62M2.98M3.7M2.8M4M
COGS % of Revenue-43.43%64.4%46.06%34.32%20.8%21.41%22.34%23.8%24.82%26.42%34.1%37.79%45.21%--------10.52%161.74%45.99%429.72%29.35%26.53%37%11.52%18.6%
Gross Profit71.37M120.87M81.38M165.54M242.48M461.86M482.62M333.74M174.67M136.15M95.72M53.88M33.72M14.44M000007.37M500K500K910K-4.55M35.38M32.32M11.12M8.24M15.3M21.5M17.5M
Gross Margin %40.54%56.57%35.6%53.94%65.68%79.2%78.59%77.66%76.2%75.18%73.58%65.9%62.21%54.79%-----100%100%100%89.48%-61.74%54.01%647.25%70.65%73.47%153%88.48%81.4%
Gross Profit Growth %-48.52%-50.84%-31.73%-47.5%-4.3%44.61%91.07%28.29%42.24%77.65%59.8%133.51%------100%1373%0%-45.05%120.01%-112.85%9.47%190.65%34.91%-46.13%-28.84%22.86%-27.69%
Operating Expenses95.97M134.81M173.18M222.16M348.35M451.36M502.27M358.01M282.9M181.71M161.35M152.1M129.67M196.54M116.75M44.16M45.1M30.93M28.18M40.73M31.13M18.76M12M34.27M69.12M37.4M13.76M10.95M32.1M29.6M35.8M
OpEx % of Revenue-63.1%75.75%72.38%94.36%77.4%81.8%83.31%123.42%100.33%124.03%186.05%239.24%745.87%-----553.06%6226%3751.2%1180.14%465.36%105.51%748.95%87.46%97.61%321%121.81%166.51%
Selling, General & Admin77.7M115M152.31M199.94M304.42M408.33M463.31M323.62M227M134.55M111.37M101.05M79.35M121.25M57.79M22.56M17.09M15.25M15.23M19.45M13.27M10.58M6.99M30.89M23.66M33.26M8.73M4.62M8.4M7.3M34.6M
SG&A % of Revenue-53.83%66.62%65.15%82.45%70.02%75.45%75.3%99.03%74.29%85.62%123.6%146.39%460.12%-----264.15%2654%2115.4%686.82%419.36%36.12%666.09%55.47%41.18%84%30.04%160.93%
Research & Development18.31M19.81M20.87M22.22M30.41M29.31M38.96M34.39M55.9M47.16M49.98M51.06M50.33M72.75M58.96M21.6M28.01M17.84M12.95M12.11M17.19M8.92M3.48M5.44M6.22M4.14M5.75M6.33M19.8M19.8M0
R&D % of Revenue-9.27%9.13%7.24%8.24%5.03%6.34%8%24.39%26.04%38.42%62.46%92.85%276.08%-----164.4%3437.2%1784%342.28%73.89%9.49%82.86%36.54%56.44%198%81.48%-
Other Operating Expenses000013.53M13.72M104K0-326K74K-482K-9K-503K-1.15M-427K00-2.16M09.17M1.21M676K-510K-2.05M39.24M0-1K-1K2.6M2.5M1.2M
Operating Income-24.6M-13.94M-91.8M-56.62M-105.87M10.5M-19.66M-24.28M-108.22M-45.55M-65.63M-98.22M-95.95M-182.11M-116.75M-44.35M-44.63M-30.38M-28.18M-31.92M-31.16M-18.91M-11.09M-38.82M-32.66M-5.08M-2.65M-7.13M-10.5M-8.1M-18.3M
Operating Margin %-13.97%-6.53%-40.15%-18.45%-28.68%1.8%-3.2%-5.65%-47.22%-25.15%-50.45%-120.14%-177.03%-691.08%------433.46%-6232.2%-3781.6%-1090.66%-527.1%-49.86%-101.7%-16.81%-63.58%-105%-33.33%-85.12%
Operating Income Growth %-84.81%-62.14%46.52%-1108.08%153.43%19.05%77.57%-137.57%30.58%33.19%-2.36%47.31%-55.98%-163.25%0.62%-46.91%-7.79%11.73%-2.45%-64.8%-70.47%71.43%-18.86%-543.21%-91.98%62.91%32.08%-29.63%55.74%-497.83%
EBITDA-21.98M-10.91M-88.88M-53.65M-102.77M13.36M-17.62M-23.42M-107.56M-44.85M-64.84M-97.41M-95.11M-181.21M-116.3M-44.25M-44.53M-29.79M-27.93M-31.54M-30.37M-18.1M-10.34M-38.15M-24.37M16.14M-223K-4.81M-7.9M-5.6M-17.1M
EBITDA Margin %-12.49%-5.11%-38.88%-17.48%-27.84%2.29%-2.87%-5.45%-46.92%-24.76%-49.85%-119.15%-175.48%-687.69%------428.21%-6073.2%-3619.6%-1016.52%-517.99%-37.2%323.27%-1.42%-42.9%-79%-23.05%-79.53%
EBITDA Growth %76.44%87.72%-65.67%47.8%-869.32%175.83%24.78%78.23%-139.83%30.84%33.43%-2.42%47.51%-55.81%-162.83%0.62%-49.44%-6.69%11.45%-3.86%-67.79%-75.06%72.9%-56.56%-250.97%7338.12%95.37%39.08%-41.07%67.25%-405.36%
D&A (Non-Cash Add-back)2.62M3.03M2.92M2.96M3.1M2.86M2.04M859K669K708K783K812K844K892K449K100.43K99.97K582K254.19K386K795K810K754K671K8.29M21.22M2.42M2.32M2.6M2.5M1.2M
EBIT-20.52M-36.04M-77.19M-53.66M-103.79M11.42M-14.76M-15.86M-107.3M-45.05M-57.31M-98.11M-40.62M-135.51M-152.77M-66.89M-250M-55.74M-20.12M-38.82M-30.63M-20.1M11.65M-38.82M-33.74M-5.08M-2.65M-7.13M-10.5M-8.1M-18.3M
Net Interest Income10.41M10.85M13.4M11.86M2.8M1.09M2.3M1.87M-7.8M-9.34M-18.44M-20.05M-18.48M-33.84M-17.55M230K34K-7.45M7.49M000000000000
Interest Income10.41M10.85M13.4M11.86M2.82M1.22M4.9M8.5M1.07M429K234K00343K544K231K53K198.94K9.63M000000000000
Interest Expense07K7K8K15K129K2.6M6.63M8.87M9.77M18.68M20.05M18.48M34.18M18.09M1K19K8.23M2.14M6.46M01.8M0029.46M00024.4M800K0
Other Income/Expense7.47M-22.11M14.6M2.95M2.06M789K2.4M1.8M-8.12M-9.26M-10.76M-20.07M36.75M12.69M-53.32M-22.73M-205.4M-29.36M7.58M-7.08M3.44M-497K222K12.24M-883K366K525K-1.63M-5.5M-3.2M1.6M
Pretax Income-17.13M-36.05M-77.2M-53.67M-103.81M11.29M-17.25M-22.48M-116.35M-55.41M-76.38M-118.29M-59.2M-169.42M-170.95M-66.89M-250.09M-59.74M-20.96M-39M-27.52M-21.26M-10.39M-26.58M-33.55M-4.71M-2.12M-8.76M-16M-11.3M-16.7M
Pretax Margin %-9.73%-16.87%-33.77%-17.49%-28.12%1.94%-2.81%-5.23%-50.76%-30.59%-58.72%-144.69%-109.22%-642.94%------529.57%-5503.8%-4251.4%-1021.24%-360.9%-51.21%-94.37%-13.47%-78.1%-160%-46.5%-77.67%
Income Tax2.01M2.75M4.98M5.44M2M3.56M745K164K96K13.05M9.97M-3.09M-2.84M-3.19M9.12M2.52M-501K-440K-674K-837K-799K-698K7.33M-7.36M3.54M412K342K-27K100K600K-1.1M
Effective Tax Rate %-11.74%-7.63%-6.45%-10.14%-1.92%31.55%-4.32%-0.73%-0.08%-23.55%-13.05%2.61%4.79%1.89%-5.33%-3.76%0.2%0.74%3.22%2.15%2.9%3.28%-70.6%27.67%-10.55%-8.74%-16.13%0.31%-0.63%-5.31%6.59%
Net Income-19.14M-38.8M-82.18M-59.11M-105.8M7.73M-18M-22.64M-116.44M-67.86M-86.35M-115.2M-56.36M-166.23M-179.18M-69.42M-249.52M-59.32M-20.02M-38.17M-26.92M-20.55M3.23M-19.22M-37.08M-4.76M2.54M4.37M-28.8M-7.7M-15.6M
Net Margin %-10.87%-18.16%-35.95%-19.26%-28.66%1.33%-2.93%-5.27%-50.8%-37.47%-66.38%-140.91%-103.99%-630.82%------518.22%-5384%-4109.4%317.5%-261.02%-56.61%-95.33%16.15%38.96%-288%-31.69%-72.56%
Net Income Growth %77.79%52.79%-39.03%44.13%-1468.91%142.94%20.51%80.55%-71.58%21.41%25.05%-104.39%66.09%7.23%-158.11%72.18%-320.66%-196.27%47.54%-41.78%-31.02%-736.33%116.8%48.16%-679.08%-287.33%-41.85%115.17%-274.03%50.64%-480.49%
Net Income (Continuing)-19.14M-38.8M-82.18M-59.11M-105.8M7.73M-18M-22.64M-116.44M-68.59M-86.35M-115.2M-56.36M-166.23M-180.12M-69.42M-249.52M-59.3M-20.27M-38.17M-26.72M-20.55M-17.72M-19.22M-37.08M-5.12M-2.46M-8.73M-16.1M-11.9M-15.6M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)-0.92-1.80-4.00-3.00-5.200.38-1.00-1.32-7.80-5.00-8.20-16.60-7.20-25.60-24.80-10.60-49.80-28.00-18.20-81.60-67.00-88.0023.20-224.80-796.80-22.8060.40582.80-3840.00-1040.00-2200.00
EPS Growth %74.94%55%-33.33%42.31%-1468.42%138%24.24%83.08%-56%39.02%50.6%-130.56%71.88%-3.23%-133.96%78.71%-77.86%-53.85%77.7%-21.79%23.86%-479.31%110.32%71.79%-3394.74%-137.75%-89.64%115.18%-269.23%52.73%-454.84%
EPS (Basic)--1.80-4.00-3.00-5.200.39-0.94-1.32-7.80-5.00-8.20-16.60-6.40-20.60-24.80-10.60-49.80-28.00-18.20-81.60-67.00-92.6034.40-224.80-796.80-101.20128.40582.80-3843.80-1040.00-2200.00
Diluted Shares Outstanding20.82M20.75M20.55M20.38M20.06M20.12M19.09M17.13M14.86M13.53M10.59M9.03M8.69M8.35M7.2M6.51M5.01M2.12M1.1M468.45K401.6K202.05K138.63K85.55K46.69K209.28K42.1K7.5K7.5K7.4K7.09K
Basic Shares Outstanding20.82M20.75M20.55M19.7M20.06M19.8M18M17.13M14.86M13.53M10.53M8.98M8.69M8.05M7.2M6.51M5.01M2.12M1.1M468.45K401.6K202.05K89.7K85.55K46.69K47.03K7.49K7.5K7.49K7.4K7.09K
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Revenue contraction and losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Stabilizing After Sharp Decline

Based on reported quarterly figures, AMRN's revenue fell from $72.7M in 2025Q2 to $39.5M in 2026Q3, a decline of roughly 46% that suggests sustained erosion rather than a one-time timing effect.

The year-over-year growth rates have been negative in most recent quarters, with 2026Q2 down 42.0% and 2026Q3 down 20.4%, indicating the top line is still contracting even as the rate of decline appears to moderate. The 2025Q2 peak was likely inflated by a one-time or favorable pricing period, making the trailing comparison base unusually high. Investors should monitor whether the sequential stabilization near $40-45M per quarter holds, as further weakness would signal structural demand loss.

Gross Margin Recovering From Lows

As reported in the quarterly income statements, AMRN's gross margin moved from negative 15.4% in 2024Q4 to 40.9% in 2026Q3, a recovery that appears driven by cost normalization rather than revenue expansion.

The gross margin trajectory is volatile, peaking at 69.2% in 2025Q2 before compressing to 35.5% in 2026Q2, which suggests the gross profit line is sensitive to period-specific cost or inventory items. The current 40.9% level remains well below the 2025Q2 peak and below peer gross margins in the 77-92% range for specialty pharma names. Warrants further investigation into whether the margin rebound reflects durable cost structure improvement or temporary factors.

Operating Costs Outpace Gross Profit

Based on the reported figures, AMRN's SG&A of $14.3M in 2026Q3 consumed roughly 36% of gross profit, leaving operating losses in most recent quarters despite positive gross profit.

Operating income has remained negative across all ten reported quarters except 2024Q2 is near breakeven, indicating that the cost base has not scaled down in line with the revenue decline. SG&A remained elevated at $19.7M to $38.7M in 2025 and 2026 periods, showing limited expense flexibility. This pattern suggests negative operating leverage, where shrinking revenue compresses margins faster than costs can be reduced.

Net Income Swings Driven by Non-Operating Items

According to the reported income statements, AMRN's net income in 2026Q3 was $245K despite an operating loss of $2.4M, a gap that suggests non-operating items materially affected the bottom line.

The divergence between operating income and net income in several quarters, such as 2024Q4 where net loss was close to operating loss, points to items below the operating line such as interest or other income. Stock-based compensation has been material at $1.4M to $6.0M per quarter in several periods, and a negative SBC figure in 2025Q4 warrants review. Earnings quality appears weak given the frequent reliance on non-operating items to shift reported results.

R&D Lean Relative to SG&A Burden

As reported in the financial statements, AMRN's R&D spending of $4.2M to $6.0M per quarter represents a small fraction of total operating costs, while SG&A has absorbed most of the expense base.

SG&A consistently exceeds R&D by a wide margin, with SG&A at $14.3M against R&D of $4.2M in 2026Q3, indicating a commercially oriented cost structure rather than a research-led one. This mix may suggest the company is managing for commercial cash generation, though it also raises questions about the sustainability of the product pipeline. Investors should monitor whether SG&A is reduced further in line with revenue or whether it remains a fixed burden.

Losses Persist Despite Recent Stabilization

Based on reported quarterly results, the case against AMRN rests on continued revenue decline and operating losses in most periods, with the recent quarterly profit appearing to rely on non-operating or one-time effects.

The bear argument centers on the fact that revenue has declined for multiple consecutive quarters and that the single profitable quarter in 2026Q3 reflected a net income of only $245K against an operating loss. Negative net margins in most periods, including -37.4% in 2025Q1 and -78.0% in 2024Q4, suggest the business has not yet demonstrated a durable path to profitability. Investors should be cautious about extrapolating the recent stabilization without evidence of sustained operating income.

AMRN — Frequently Asked Questions

Quick answers to the most common questions about buying AMRN stock.

What was Amarin Corporation plc's (AMRN) revenue in 2025?

For fiscal year 2025, Amarin Corporation plc (AMRN) reported total revenue of $213.6M. This represents a 893.7% increase compared to $21.5M in 1996.

Is Amarin Corporation plc (AMRN) profitable?

Amarin Corporation plc (AMRN) reported a net loss of $38.8M for the fiscal year ending 2025.

What is Amarin Corporation plc's operating profit margin?

Amarin Corporation plc (AMRN) reported an operating income of $-13.9M, resulting in an operating profit margin of -6.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Amarin Corporation plc's gross profit and gross margin?

Amarin Corporation plc (AMRN) generated $120.9M in gross profit for the year, representing a gross profit margin of 56.6%. This demonstrates the company's core pricing power and production efficiency.